---
title: "Retension Pharmaceuticals climbs 10% in regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303973570.md"
description: "Retension Pharmaceuticals rose 10.04% to US$12.50. Down 23.45% over ten sessions."
datetime: "2026-11-02T14:35:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303973570.md)
  - [en](https://longbridge.com/en/news/303973570.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303973570.md)
generator: "portal-rs"
---

# Retension Pharmaceuticals climbs 10% in regular trading

Retension Pharmaceuticals (RTSN.US) climbed more than **10%** during regular trading to **$12.50**.

The stock is down 23.45% over the past ten sessions and sits 29.40% above its 52-week low of US$9.660.

The Nasdaq Composite is down 2.09% over the past five sessions and up 10.24% year to date.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [RTSN.US](https://longbridge.com/en/quote/RTSN.US.md)

## Related News & Research

- [Retension Pharma director Franklin M. Berger acquires 10,000 common shares for $120,000](https://longbridge.com/en/news/301760599.md)
- [Retension Pharmaceuticals adopts amended and restated bylaws ahead of IPO close](https://longbridge.com/en/news/301750965.md)
- [Anthropic’s Valuation Target Has Slipped From $2 Trillion to Under $1.5 Trillion. Here’s Why](https://longbridge.com/en/news/305493732.md)
- [MaxLinear Stock In Focus After New AI Optics Power Chip Launch](https://longbridge.com/en/news/305513238.md)
- [Visa says card enumeration fuels more than $1 billion in annual global fraud losses](https://longbridge.com/en/news/305494235.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**